24/7 Wall St. Quick Read Even after the VIK stock rallied from about $57.50 to $68.75, Jefferies sees more upside ahead. After plummeting from about $67.50 to $43.85 on healthcare policy uncertainty, Morgan Stanley upgraded the DOCS stock to an overweight rating with a $65 price target. Goldman Sachs just upgraded Las Vegas Sands to a buy rating with a price target of $80 from $64 a share. If you’re thinking about retiring or know someone who is, there are three quick questions causing many Americ ...

Doximity, Inc. ( DOCS ) reported a 2Q26 non-GAAP EPS of $0.45. It's a figure that beat estimates by about $0.07. Revenue also came in above expectations, beating consensus by $10.91 with a figure of $168.5 million. Revenue was also up 23.2% year-over-year. TheI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scien ...

Core Insights - Doximity (DOCS) has been underperforming in the market despite its strong cash flow and niche dominance, often trading like a penny stock when market sentiment shifts [1] Company Analysis - Doximity is recognized for its robust cash generation and market position, yet its stock price does not reflect its underlying economic strength [1] - The company operates in a sector where market perceptions can significantly impact stock performance, leading to volatility [1] Investment Perspective - The investment strategy focuses on identifying mispriced opportunities where market valuations diverge from a company's fundamental performance [2] - There is an emphasis on cash flow durability, balance sheet strength, and understanding the risks associated with capital structures [2] - The approach seeks to capitalize on cyclical industries and under-followed mid-cap companies, where market expectations may not align with reality [2] - Asymmetric setups are targeted, particularly in cases where companies have already faced market punishment while their fundamentals are stabilizing or improving [2]

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1] Zacks Style Scores - Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe [2] - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A being the highest score [2] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score evaluates a company's future prospects by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends by assessing factors like one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with attractive value, strong growth forecasts, and promising momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to ensure potential upside [10] Earnings Estimate Revisions - The direction of earnings estimate revisions is crucial when selecting stocks, as stocks with lower ranks (e.g., 4 or 5) may still decline despite having high Style Scores [11] Company Spotlight: Doximity - Doximity is a leading professional medical network in the U.S., reaching over 80% of physicians and 60% of advanced practice providers [12] - Doximity holds a 3 (Hold) Zacks Rank and a VGM Score of B, indicating potential for growth [12] - The company has a Growth Style Score of A, with a forecasted year-over-year earnings growth of 10.6% for the current fiscal year [13] - Recent analyst revisions have increased the earnings estimate for fiscal 2026, with the Zacks Consensus Estimate rising to $1.57 per share [13] - Doximity has an average earnings surprise of +27.9%, making it a strong candidate for growth investors [13][14]

Core Insights - Doximity, Inc. is highlighted as a strong digital health stock, with Morgan Stanley maintaining an Equal-Weight rating and a price target of $62, citing stronger-than-expected growth driven by the video module business [1][2] - The company reported Q2 FY26 revenue of $168.5 million, reflecting a 23% year-over-year increase, and adjusted EBITDA of $100.8 million, indicating a margin of approximately 60% [3] - Management guidance for Q3 FY26 revenue is set between $180 million and $181 million, representing about a 7% year-over-year growth, with FY26 revenue projected at $640 million to $646 million, approximately a 13% year-over-year increase [3] Business Overview - Doximity operates as a digital platform tailored for medical professionals, providing networking tools, telehealth services, and physician marketing solutions [4] - The platform includes a HIPAA-compliant communication suite and collaborates with pharmaceutical and hospital systems to facilitate targeted outreach to clinicians across the United States [4] Competitive Landscape - Concerns regarding competitive pressure from OpenEvidence have been addressed, with no significant overlap or measurable impact on Doximity's business reported so far [2]

Core Viewpoint - Doximity, Inc. (NYSE:DOCS) is currently viewed as an expensive stock with disappointing recent performance, leading to a recommendation against buying it at this time [1]. Company Overview - Doximity operates a digital platform that provides medical professionals with tools for collaboration, career management, research updates, documentation, and virtual patient care [1]. Recent Performance - The stock experienced a less than 1% increase since Jim Cramer's comments were aired, indicating a lack of strong market confidence [1]. Analyst Commentary - Jim Cramer expressed that Doximity had a "bad miss" in its recent quarter, which was unexpected for a high-growth company, leading to a negative outlook on the stock [1].

Group 1: Doximity, Inc. (NYSE:DOCS) - Doximity reported quarterly earnings of 45 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company achieved quarterly sales of $168.525 million, surpassing the analyst consensus estimate of $157.614 million [1] - Jim Cramer advised waiting before purchasing Doximity shares, stating they are "still too expensive" [1] Group 2: IREN Limited (NASDAQ:IREN) - IREN reported quarterly earnings of $1.08 per share, significantly beating the consensus estimate of 14 cents [2] - The company's quarterly revenue was $240.3 million, exceeding the Street estimate of $235.5 million and up from $49.57 million in the same period last year [2] - Jim Cramer recommended selling half of IREN stock [2] Group 3: Boise Cascade Company (NYSE:BCC) - Boise Cascade reported quarterly earnings of 58 cents per share, missing the analyst consensus estimate of 76 cents per share [3] - The company reported quarterly sales of $1.668 billion, which beat the analyst consensus estimate of $1.623 billion [3] - Jim Cramer expressed concerns about the housing sector and suggested that Boise Cascade is too leveraged to a specific part of the market [3] Group 4: Price Action - Doximity shares fell 3.3% to settle at $50.96 [5] - IREN shares declined 2.9% to close at $55.70 [5] - Boise Cascade shares rose 0.9% to settle at $70.28 [5]

Core Insights - The article emphasizes the importance of utilizing Zacks Premium for investors to enhance their stock market strategies and confidence in investing [1][2] Zacks Style Scores - Zacks Style Scores provide a unique rating system for stocks based on value, growth, and momentum characteristics, aiding investors in selecting securities with high potential for market outperformance over the next 30 days [3][4] - Stocks are rated from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Score identifies attractive and discounted stocks using various financial ratios such as P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [5] Momentum Score - The Momentum Score helps investors capitalize on price trends by evaluating short-term price changes and earnings estimate shifts [6] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with the best value, growth potential, and momentum, serving as a strong indicator alongside the Zacks Rank [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8][10] - There are typically over 800 top-rated stocks available, making it essential to utilize Style Scores for effective selection [9] Stock Highlight: Doximity (DOCS) - Doximity is the leading professional medical network in the U.S., reaching over 80% of physicians and 60% of advanced practice providers, offering a HIPAA-compliant platform for various digital solutions [12] - Doximity holds a 2 (Buy) rating on the Zacks Rank and has a VGM Score of B, indicating strong potential for growth [12][13] - The company is projected to achieve year-over-year earnings growth of 7.8% for the current fiscal year, with recent upward revisions in earnings estimates [13]

Group 1 - Doximity (DOCS) shares fell approximately 14% despite reporting better-than-expected Q2 FY26 financial results [3] - The decline in share price was attributed to concerns over healthcare-policy-related uncertainty affecting clients' annual budgets [3]

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 45 cents for Q2 fiscal 2026, a 50% increase year over year, exceeding the Zacks Consensus Estimate by 18.4% [1][8] - The company's revenues reached $168.5 million in Q2, reflecting a year-over-year growth of 23.2% and surpassing the Zacks Consensus Estimate by 6.8% [2][8] Revenue Breakdown - Subscription revenues amounted to $159.5 million, up 23% year over year, driven by increased spending from existing customers and a net revenue retention rate of 118% [3] - Other revenues totaled $9.1 million, marking a 25.9% increase year over year [3] Margin Analysis - Gross profit increased by 23.5% year over year to $152.1 million, with a gross margin expansion of 30 basis points to 90.3% [4][8] - Operating profit was $63.7 million, a 19.8% increase from the prior year, although the operating margin contracted by 100 basis points to 37.8% [5][8] Financial Position - Doximity ended Q2 fiscal 2026 with cash and cash equivalents of $169.2 million, up from $137.3 million at the end of Q1 [6] - Cumulative net cash from operating activities was $156 million, compared to $109.6 million a year ago [6] Future Guidance - For Q3 fiscal 2026, Doximity expects revenues between $180 million and $181 million, exceeding the Zacks Consensus Estimate of $178.2 million [7] - The full fiscal year revenue outlook has been raised to between $640 million and $646 million, up from the previous estimate of $628 million to $636 million [9] Product and Engagement Highlights - The company introduced multiple product updates focused on AI and workflow expansion, including the integration of Pathway's medical dataset into DoxGPT [11] - Record engagement was noted with over 650,000 unique prescribers utilizing various digital tools, and AI-optimized program adoption accounted for 40% of bookings [12]